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cense.Abstract Introduction: The cartilage oligomeric matrix protein (COMP) is a glycoprotein, which
occurs mainly in an articular cartilage. The amount of this protein increases under the inﬂuence of
cytokines and growth factors. As a result of various diseases that cause damage to cartilage, frag-
ments of matrix protein are released into synovial ﬂuid and then into blood. The assessment of
matrix protein level in serum, for example COMP, permits the establishment of the degree of car-
tilage damage in inﬂammatory joint diseases, and permits observation of the effectiveness of the
treatment.
Aim of the work: To assess serum COMP level, as a marker for cartilage degradation, in SLE and
OA patients and to ﬁnd a correlation between serum COMP level and other markers as well as
activity of disease, disease duration and the age of the patients.
Patients and methods: Blood was collected from 40 systemic lupus erythematosus (SLE) patients
group I, [the patients were further subdivided into two subgroups, group (Ia) comprised 20 SLE
patients received 1 g IV methylprednisolone (MP) daily for three successive days, group (Ib) com-
prised 20 SLE patients did not receive IV methylprednisolone (MP)], and from 20 patients with.com (S.M. Fawzy),
beni).
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14 S.M. Fawzy et al.knee osteoarthritis (OA) group II who constituted the control group. Serum COMP level was deter-
mined using an inhibition enzyme-linked immunosorbent assay (ELISA).
Results: The measured values of the serumCOMP level in SLE patients ranged from 1.32 to 1.71 lg/
ml with amean of 1.51 ± 0.13 lg/ml in group (Ia), and ranged from 2.43 to 3.56 lg/ml with amean of
2.86 ± 0.31 lg/ml in group (Ib).While inOAgroup (II) the value of serumCOMPranged from0.97 to
2.65 lg/mlwith ameanof 1.25 ± 0.37 lg/ml.We found signiﬁcantly elevatedCOMP levels in the SLE
group (Ib) compared to the SLE group (Ia) patients and OA group (II) (p< 0.001). We found a sta-
tistically signiﬁcant positive correlationswith the number of tender joints (correlation coefﬁcient Pear-
son’s: r= 0.45, p< 0.01), the number of swollen joints (r= 0.55, p< 0.001), SLAMvalue (r= 0.56,
p< 0.001). A signiﬁcant positive correlation was found between serum COMP level and the ESR
value in the ﬁrst hour (r= 0.35, p< 0.001). While the serum COMP level was independent of the
patients’ age (r= 0.04, p=NS), disease duration (r= 0.03, p=NS) and morning stiffness dura-
tion (r= 0.05, p=NS). Also aNegative correlationwas found between the serumCOMP level and
haemoglobin value (r= 0.11, p=NS).As regards theOAgroup, no correlationwas foundbetween
the serum COMP level and patients’ age (r= 0.05, p=NS) and disease duration (r= 0.24,
p=NS). There were positive correlations between serum COMP and WOMAC index score for the
lower limbs (r= 0.64, p< 0.05).
Conclusion: The serum COMP level can be an important marker of disease activity and cartilage
destruction in SLE and OA Patients, and that serum levels of COMP can be used as a parameter
formonitoring the therapy response in SLEpatients undergoing an intravenous bolus steroid therapy.
 2011 Egyptian Society for Joint Diseases and Arthritis. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Cartilage oligomeric matrix protein (COMP)/thrombospon-
din-5, a non-collagenous extra cellular matrix (ECM) glyco-
protein distributed abundantly in cartilage [1], appears to
catalyze ﬁbril formation by promoting early association of col-
lagen molecules, leading to an increased rate of ﬁbrilogenesis
and more distinct ﬁbril organization [2]. COMP might func-
tion to support matrix interactions in ECM of cartilage [3].
Association of COMP with granulin–epithelin precursor, which
promotes chondrocyte proliferation [4], also suggests that COMP
is a key molecule in the interplay between cells and ECM in
cartilage [5]. This protein has a complete molecular mass of
524 kD, the structure of a pentamer and consists of ﬁve arms
containing a peripheral globular domain, a ﬂexible strand
and a central assembly domain where the ﬁve arms are con-
nected in a cylindrical structure [6–9]. COMP can be found
in human articular cartilage, meniscus, cruciate ligament, ten-
don and synovial membranes [10]. The amount of this protein
increases under the inﬂuence of cytokines and growth factors
(such as transforming growth factor-b1-TGFb1). As a result
of various diseases which damage articular cartilage, fragments
of matrix protein are released into synovial ﬂuid and then into
blood. The assessment of the matrix protein level in serum, for
example COMP, permits the establishment of the degree of
cartilage damage in inﬂammatory joint diseases such as rheu-
matoid arthritis [11–15] or OA [16,17] and permits observation
of the effectiveness of the treatment of these diseases [18–21]. It
is interesting how COMP functions in SLE patients under ste-
roid treatment over years. Over time, this treatment may be
destructive to cartilage in SLE patients, causing degenerative
changes in joints. The degree of destruction of cartilage can
be measured with the new cartilage marker COMP [22]. The
aim of this study was to assess serum COMP level, as a marker
for cartilage degradation, in SLE and OA patients and to ﬁnd
a correlation between serum COMP level and other markers aswell as activity of disease, disease duration and the age of the
patients.
2. Patients and methods
2.1. Subjects
A total of 40 consecutive SLE patients (group I) were included
in the present study all fulﬁlling the updated American College
of Rheumatology (ACR) revised criteria for the classiﬁcation
of SLE [23]. The patients were further subdivided into two sub-
groups, group (Ia) comprised 20 SLE patients received 1 g IV
methylprednisolone (MP) daily for three successive days,
group (Ib) comprised 20 SLE patients who did not receive
IV methylprednisolone (MP). All Patients were recruited from
the Rheumatology department and outpatient clinic of Cairo
University Hospitals. After taking their informed consent, full
history, thorough general and locomotor system examination,
laboratory and relevant radiological investigations were done
for all the patients. Disease activity was assessed for all the pa-
tients using the SLAM index [24].
Twenty age matched patients with knee OA who fulﬁlled
the ARA Classiﬁcation Criteria for Osteoarthritis [25] were
considered as a control group (group II). The selected patients
had unilateral or bilateral knee effusion with exclusion of pa-
tients with suggestive history of secondary OA.
The patients were assessed by Western Ontario and
McMaster universities osteoarthritis index (WOMAC) ques-
tionnaires for the lower limbs and antero-posterior knee X
ray assessed by Kellgren and Lawrence (K/L) grading scale
to classify the degree of OA [26,27].
For all patients venous samples were obtained for routine
laboratory investigations (CBC, liver and kidney function
and urine analysis), the blood sample of group (Ia) patients
was obtained 2–10 days after the ﬁrst treatment with IV
steroid.
Table 1 Shows demographic and clinical characteristics of the
SLE group I (n= 40).
Feature Group Ia (n= 20)Group Ib (n= 20)
Sex M/F 3/17 3/17
Age (y)
Range 19–42 22–49
Mean ± SD 27.656 ± 0.42 31.80 ± 7.88
Disease duration (y)
Range 1–19 1–17
Mean ± SD 6.004 ± 0.66 6.805 ± 0.24
No. of tender joints
Range 0–13 0–13
Mean ± SD 6.954 ± 0.31 5.354 ± 0.17
No. of swollen joints
Range 0–5.00 0–10.00
Mean ± SD 2.101 ± 0.92 2.052 ± 0.58
Morning stiﬀness (min)
Range 0–120 0–180
Mean ± SD 44.25 ± 28.99 49.254 ± 5.89
ANA
Seropositive 20 (100%) 17 (85%)
Seronegative 0 3 (15%)
SLAM
Range 18–35 9–23
Mean ± SD 27.054 ± 0.67 15.053 ± 0.91
Mild disease activity (1–28) 31 (77.5%)
Moderate disease act (29–50) 9 (22.5%)
Sever disease activity >51 0
Data are the mean ± SD; SLAM= systemic lupus activity.
Table 2 Shows the laboratory data of the SLE group
(n= 40).
Items Group Ia Group Ib
Hb (gm/dl)
Range 4.50–11.40 6.90–15.70
Mean ± SD 14.80 ± 23.48 11.27 ± 2.15
WBC (dl)
Range 3.10–26.30 4.40–21.10
Mean ± SD 7.14 ± 4.97 8.97 ± 3.93
PLT (dl)
Range 80–551.00 121.00–601.00
Mean ± SD 298.50 ± 128.41 303.40 ± 115.64
ESR ﬁrst (mm/h)
Range 15–150.00 6.00–140.00
Mean ± SD 78.70 ± 44.48 54.60 ± 40.65
Twenty-four hours urinary prot. in gram
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room temperature and was then centrifuged and stored at
80 C until analysed following a standardized protocol using
the commercially available kits. The COMP level was deter-
mined using an inhibition enzyme-linked immunosorbent as-
say (ELISA), polyclonal antibodies raised in a rabbit against
the bovine protein were used. The blood serum is diluted four
times before applying it to a plate that contains COMP anti-
gens, the plate was washed to remove all the other components
of the blood serum then a secondary antibody that binds to the
COMP antibodies to the plate was applied and the plate was
washed again. This secondary antibody is chemically linked
to an enzyme which the plate now contains in proportion to
the amount of secondary antibody. Then a substrate was ap-
plied to make the enzyme detectable. This typically causes
the enzyme to change color or ﬂuorescence. The results of an
ELISA were reported as a number so that the color change
was quantiﬁed in some way. The threshold for a positive result
was established. This is the most difﬁcult part of the ELISA
because the result can cover a wide range. A minimum value
must, therefore, be selected to identify a positive result. An
ELISA was performed on a control sample with a known con-
centration of the analyte and the signal that this sample pro-
duces was set as the standard. Any test sample that produces
a stronger signal than the control sample is a positive result.
In SLE patients, serological examinations were made to dis-
cover the presence of:
(1) Anti-nuclear antibody and anti-ds DNA tests were car-
ried out by indirect Immunoﬂuorescence (IIF) technique.
(2) Anti cardiolipin antibodies (IgG and IgM) and Anti Ro
(SSA) and AntiLa (SSB) were detected by ELISA.
2.2. Statistics
The data were coded and entered using the statistical package
SPSS version 15. The data were summarized using descriptive
statistics: mean ± standard deviation (±SD), or frequencies
(n) and percentages (%). Statistical differences between groups
were tested using Chi Square test (v2) for qualitative variables,
Independent sample t-test and ANOVA (analysis of variance)
for quantitative normally distributed variables and non-
parametric Mann Whitney test and Kruskal Wallis test for
not normally distributed quantitative variables. Correlations
were done to test for linear relations between variables. A prob-
ability value (p value) 0.05 was considered statistically
signiﬁcant.Range 0–59 0–2.10
Mean ± SD 6.06 ± 15.11 0.42 ± .543. Results
Demographic, clinical and laboratory characteristics of the
study SLE group are shown in Tables 1 and 2, while demo-
graphic and clinical data of OA group are shown in Table 3.
The measured values of the serum COMP level in SLE pa-
tients ranged from 1.32 to 1.71 lg/ml with a mean of
1.51 ± 0.13 lg/ml in group (Ia), and ranged from 2.43 to
3.56 lg/ml with a mean of 2.86 ± 0.31 lg/ml in group (Ib).
While in OA group (II) the value of serum COMP ranged from
0.97 to 2.65 lg/ml with a mean of 1.25 ± 0.37 lg/ml. We
found signiﬁcantly elevated COMP levels in the SLE group(Ib) compared to the SLE group (Ia) patients and OA group
(II) (p< 0.001) (Table 4 and Fig. 1).
According to the Pearson’s correlation coefﬁcient, in SLE
patients the serum COMP level showed statistically signiﬁcant
positive correlations with the number of tender joints (correla-
tion coefﬁcient Pearson’s: r= 0.45, p< 0.01), the number of
swollen joints (r= 0.55, p< 0.001), SLAM value (r= 0.56,
p< 0.001) in Table 5. A signiﬁcant positive correlation was
found between serum COMP level and the ESR value in the
1st hour (r= 0.35, p< 0.001) (Fig. 2). While the serum
Table 5 Shows correlation between serum COMP and vari-
ous disease parameters in SLE group I (n= 40).
No. tender joint
Pearson correlation 0.451
Sig. (2-tailed) 0.004
N 40
No. swollen joint
Pearson correlation 0.554
Sig. (2-tailed) 0.000
N 40
SLAM
Pearson correlation 0.561
Sig. (2-tailed) 0.000
N 40
ESR
Pearson correlation 0.357
Sig. (2-tailed) 0.024
N 40
Hb
Pearson correlation 0.109
Sig.(2-tailed) 0.503
N 40
Table 4 Shows the correlation between serum COMP level in
SLE & OA groups.
N Mean Std.
deviation
Minimum Maximum P value
Comp MP + 20 1.51 0.13 1.32 1.71 .000
Comp MP  20 2.86 0.31 2.43 3.56
Control 20 1.25 0.37 0.97 2.65
Figure 1 Shows the comparison between serum COMP levels in
SLE & OA patients.
Figure 2 Correlation between ESR value and serum COMP
level in SLE patients’ group. The linear regression line is shown.
Table 3 Shows the demographic and clinical data of the OA
group II (n= 20).
Sex M/F 4/16
*Age (years) 59 ± 8.2
*Disease duration 10.5 ± 5.8
*The WOMAC index score 12.5 ± 3.6
*K/L scale
Grade III 16 patients (60%)
Grade IV 4 patients (40%)
Data are the mean ± SD, WOMAC=Western Ontario and
McMaster universities osteoarthritis index, K/L = Kellgren and
Lawrence (K/L) grading scale.
Figure 3 Negative correlation between haemoglobin value and
the serum COMP level in SLE patients. The linear regression line
is shown.
16 S.M. Fawzy et al.COMP level was independent of the patients’ age (r= 0.04,
p=NS), disease duration (r= 0.03, p=NS) and morning
stiffness duration (r= 0.05, p=NS).
Decreased haemoglobin level below 11.0 g/dl was consid-
ered as an abnormal value. We found that in patients with de-
creased haemoglobin level the average serum COMP level was
higher than in patients with normal haemoglobin level, Table 5.
So a negative correlation was found between the serum COMP
level and haemoglobin value (r= 0.11, p=NS) (Fig. 3).
Particular interest was shown on arthritis presence, 16 pa-
tients (80%) had arthritis of hands without degenerative
changes, at disease ﬂare in group Ia and ﬁfteen patients
(75%) had arthritis in group Ib. We found that serum COMP
Table 6 Shows comparison between serum COMP level and
arthritis in SLE sub groups.
Group N Mean Std.
deviation
Minimum Maximum P value
Ia
ve arthritis 4 1.55 0.12 1.41 1.71 0.420
+ve arthritis 16 1.56 0.13 1.42 1.72
Ib
ve arthritis 5 2.76 0.40 2.43 3.43 0.315
+ve arthritis 15 2.89 0.28 2.52 3.56
Serum COMP and their correlations with various disease parameters 17level was higher in group Ib (were not on MP) than in group Ia
(on MP). However, no signiﬁcant differences were found be-
tween the serum COMP level and arthritis presence in both
groups, p=NS (see Table 6).
As regards to the OA group, no correlation was found be-
tween the serum COMP level and patients’ age (r= 0.05,
p=NS) and disease duration (r= 0.24, p=NS). There were
positive correlations between serum COMP and WOMAC in-
dex score for the lower limbs (r= 0.64, p< 0.05).
4. Discussion
The cartilage oligomeric matrix protein (COMP), also known
as thrombospondins (TSP-5), is expressed in cartilage, tendon,
vitreous, and vascular smooth muscle cells [28]. Serum COMP
may predict joint damage in rheumatoid arthritis (RA) [29,30]
and in systemic lupus erythematosus (SLE) [22]. Increased ser-
um COMP was reported in osteoarthritis (OA) and after car-
tilage injury [31,32]. Recently, cartilage oligomeric matrix
protein (COMP), which is an important constituent of the
non-collagenous matrix within the hyaline cartilage needed
to maintain the properties and integrity of collagen network
[33], has been suggested as a biomarker for increased cartilage
damage and/or metabolism arising from exercise [34–37]. It
consists of ﬁve identical glycoprotein subunits. The presence
of COMP in synovial ﬂuid and serum is lower than COMP
puriﬁed from cartilage [38].
In this study, serum concentrations of antigenic fragments
of a cartilage-speciﬁc component, COMP, were found to be
increasing in SLE patients. Patients with arthritis had higher
COMP concentration in comparison with patients without
arthritis, and we found that serum COMP level was lower in
arthritic patients who received IV MP than in arthritic patients
who did not receive IV MP but not to a statistically-signiﬁcant
extent. No correlation was found between the serum COMP le-
vel and patient’s age, disease duration and morning stiffness
duration. Forslind et al. [12] explain that this tissue-speciﬁc
protein merely reﬂects generalised inﬂammation, and, there-
fore, that measurement of COMP in serum should provide
information, which is not provided by conventionally used
measures of inﬂammation. In our study, we found a signiﬁcant
positive correlation between serum COMP level and ESR va-
lue, number of tender joints, number of swollen joints and
SLAM value as well as a negative correlation between serum
COMP level and haemoglobin value. We assumed that COMP
correlates positively with the inﬂammation marker ESR in
SLE.
However in the study by Forslind et al. [12], the serum
COMP level in their SLE patients did not correlate withdisease activity. However, this study was carried out on a small
group of only nine SLE patients and only three of them had
arthritis.
In SLE patients in Forslind’s study and in our own, the ser-
um COMP level was increased. It is possible that the COMP,
although it is in part related to type 2 collagen, may also be re-
lated to some components of synovial tissue, tendon, ligaments
or even cardiac tissues, or for that matter types 4, 9 or 10 col-
lagen or even ﬁbrin.
Our results in this study, also investigating the changes in
serum levels of COMP during the treatment regime, indicate
that intravenous treatment with steroids in SLE patients may
have a rapid chondroprotective effect within 10 days. COMP
seems to be a valuable parameter for monitoring the therapy
response in patients with RA and is useful for the long-term
control of cartilage turnover and the chondroprotective effect
of different treatment modalities.
In conclusion, we found that the SLE patients had an in-
creased serum COMP level and that serum levels of COMP
can be used as a parameter for monitoring the therapy re-
sponse in SLE patients undergoing an intravenous bolus ste-
roid therapy.
The minor point of this study is the small patient group, so
further studies in a larger, unselected population of patients
are required to verify the ﬁndings and to prove that COMP
not only as a predicting factor [38], but also as a valuable
parameter for the assessment of therapy response in patients
with SLE. It is possible that in inﬂammatory joint diseases
there is not only a higher cartilage breakdown, but also an ele-
vated synthesis of COMP.
In a few studies, serum COMP level in knee osteoarthritis
was examined [16,17]. Peterson et al. [15] examined the concen-
tration of serum COMP in 38 patients with chronic knee pain
(duration > 3 months) with or without changes in radiographs
of both knee joints typical for osteoarthritis of the knee at the
3-year follow-up. The authors proved that in patients with
chronic knee pain, increased concentration of COMP in serum
can be found early as markers of early serious knee osteoar-
thritis. Vilim et al. [16], at the 3-year follow-up observation
of 48 patients with symptomatic primary knee osteoarthritis,
examined the serum COMP level and correlation with changes
in joint space width according to Kellgren–Lawrence,
Lequesne and WOMAC indices over 3 years.
Changes in joint space width (summed for both knees) cor-
related positively with baseline as well as study end period ser-
um COMP level. Serum COMP level can be a prognostic
marker of disease progression. High COMP levels, persisting
over a 3-year study period in the patients with radiographic
progression, indicated differences in disease activity detectable
throughout the entire follow-up.
In our study there was a positive correlation between
COMP levels and WOMAC index pain scale for the lower limb
of the affected patients. The laboratory tests were normal in
knee osteoarthrosis patients so we decided not to examine ser-
um COMP correlation with markers of inﬂammation.
Increasing serum COMP level in both SLE and knee OA
suggests that the serum concentration of this marker can re-
ﬂect changes in the cartilage.
In conclusion, we noted the following points:
– Increased serum COMP level was found in both: SLE and
knee OA.
18 S.M. Fawzy et al.– A positive correlation was found between the serum COMP
level and such data as ESR value, number of tender joints,
number of swollen joints and SLAM value, and a negative
correlation was found between serum COMP level and hae-
moglobin value in SLE patients.
– SLE patients with arthritis had higher COMP concentra-
tion in comparison with patients without arthritis, and we
found that serum COMP level was lower in arthritic
patients who received IV MP than in arthritic patients
who did not receive IV MP.
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